应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02511 君圣泰医药-B
未开盘 08-12 16:08:06
3.520
-0.175
-4.74%
最高
3.900
最低
3.300
成交量
47.80万
今开
3.900
昨收
3.695
日振幅
16.24%
总市值
23.58亿
流通市值
23.58亿
总股本
6.70亿
成交额
163.78万
换手率
0.07%
流通股本
6.70亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
君圣泰医药-B(02511)存仓市值总计2.87亿港元 其中股东向中信证券经纪香港存入5260.1万股
智通财经 · 08-10 08:17
君圣泰医药-B(02511)存仓市值总计2.87亿港元 其中股东向中信证券经纪香港存入5260.1万股
君圣泰医药-B完成配售9871万股新股
新浪港股 · 08-09
君圣泰医药-B完成配售9871万股新股
君圣泰医药-B(02511):5日内累涨超30%,折价配售是妙手回春还是饮鸩止渴?
智通财经 · 08-08
君圣泰医药-B(02511):5日内累涨超30%,折价配售是妙手回春还是饮鸩止渴?
君圣泰医药-B:8月7日发行98,710,000股 占已发行股本17.28%
公告速递 · 08-07
君圣泰医药-B:8月7日发行98,710,000股 占已发行股本17.28%
君圣泰医药-B(02511)完成约2.25亿港元一般性授权配售 逾9,871万股新股发行价2.28港元/股
公告速递 · 08-07
君圣泰医药-B(02511)完成约2.25亿港元一般性授权配售 逾9,871万股新股发行价2.28港元/股
君圣泰医药-B(02511.HK)完成配售9871万股 净筹约2.224亿港元
智通财经 · 08-07
君圣泰医药-B(02511.HK)完成配售9871万股 净筹约2.224亿港元
君圣泰医药-B7月股份变动月报表:股本维持不变
公告速递 · 08-03
君圣泰医药-B7月股份变动月报表:股本维持不变
君圣泰医药-B(02511)拟折让约12.31%发行合共最多9900万股配售股份
智通财经 · 07-31
君圣泰医药-B(02511)拟折让约12.31%发行合共最多9900万股配售股份
君圣泰医药-B(02511.HK)拟折让约12.31%发行合共最多9900万股配售股份
智通财经 · 07-31
君圣泰医药-B(02511.HK)拟折让约12.31%发行合共最多9900万股配售股份
君圣泰医药-B(02511)拟配售9,900万股 预计募资净额约2.23亿元港元
公告速递 · 07-31
君圣泰医药-B(02511)拟配售9,900万股 预计募资净额约2.23亿元港元
君圣泰医药-B(02511):HTD1801随机对照临床研究获积极评价
智通财经 · 07-10
君圣泰医药-B(02511):HTD1801随机对照临床研究获积极评价
君圣泰医药-B6月无新增发行或股份变动
公告速递 · 07-02
君圣泰医药-B6月无新增发行或股份变动
格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓!
格隆汇 · 06-29
格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓!
君圣泰医药-B(02511)授予董事股份购回授权 规模达已发行股本一成
公告速递 · 06-02
君圣泰医药-B(02511)授予董事股份购回授权 规模达已发行股本一成
君圣泰医药-B更新5月股份变动月报表,股本维持稳定
公告速递 · 06-01
君圣泰医药-B更新5月股份变动月报表,股本维持稳定
格隆汇个股放量排行榜 | 5月9日
格隆汇 · 05-09
格隆汇个股放量排行榜 | 5月9日
君圣泰医药-B(02511):陈明宇获委任为独立非执行董事
智通财经 · 05-04
君圣泰医药-B(02511):陈明宇获委任为独立非执行董事
君圣泰医药-B更新4月股份变动月报表,股本维持稳定
公告速递 · 05-04
君圣泰医药-B更新4月股份变动月报表,股本维持稳定
君圣泰医药-B(02511)聚焦CKM创新疗法,2025年度亏损收窄至2.32亿元
公告速递 · 04-29
君圣泰医药-B(02511)聚焦CKM创新疗法,2025年度亏损收窄至2.32亿元
君圣泰医药-B(02511.HK)授出最高1500万港元贷款
中金财经 · 04-27
君圣泰医药-B(02511.HK)授出最高1500万港元贷款
加载更多
公司概况
公司名称:
君圣泰医药-B
所属市场:
SEHK
上市日期:
--
主营业务:
君圣泰医药是一家生物制药公司,专注于就代谢及消化系统疾病的治疗发现、开发及商业化多功能及多靶点疗法。该公司自主开发了多个候选产品的产品管线,涵盖代谢和消化疾病的多种适应症,其中部分产品处于临床阶段。该公司的核心产品HTD1801(小檗碱熊去氧胆酸盐)是一种新分子实体,作为肠肝抗炎代谢调节剂,靶向调节对人体代谢过程中至关重要的多个通路,包括与代谢及消化系统疾病相关的通路。该公司在美国、中国大陆、香港和澳大利亚开展业务。
发行价格:
--
{"stockData":{"symbol":"02511","market":"HK","secType":"STK","nameCN":"君圣泰医药-B","latestPrice":3.52,"timestamp":1786522086251,"preClose":3.695,"halted":0,"volume":478000,"delay":0,"changeRate":-0.047361299052773975,"floatShares":670000000,"shares":670000000,"eps":-0.51,"marketStatus":"未开盘","change":-0.175,"latestTime":"08-12 16:08:06","open":3.9,"high":3.9,"low":3.3,"amount":1637780,"amplitude":0.162382,"askPrice":3.525,"askSize":20000,"bidPrice":3.47,"bidSize":7500,"shortable":0,"etf":0,"ttmEps":-0.405,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786584600000},"marketStatusCode":0,"adr":0,"listingDate":1703174400000,"exchange":"SEHK","adjPreClose":3.695,"openAndCloseTimeList":[[1786498200000,1786507200000],[1786510800000,1786521600000]],"volumeRatio":0.24404791139555515,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02511","defaultTab":"news","newsList":[{"id":"2658660573","title":"君圣泰医药-B(02511)存仓市值总计2.87亿港元 其中股东向中信证券经纪香港存入5260.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660573","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658660573?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:17","pubTimestamp":1786321077,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,8月7日,君圣泰医药-B(02511)出现仓位异动,存仓市值总计2.87亿港元,占比14.73%。该公司股东将股票存入中信证券经纪香港5260.1万股,持股比例增加5.57%。君圣泰医药截至2025年12月31日止年度业绩显示,该集团取得其他收入1900.7万元,同比减少72.04%;公司拥有人应占亏损2.45亿元,同比减少35.84%;每股亏损0.51元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245094.SGD","06030","LU1064131003.USD","LU1997244956.HKD","LU2580892862.HKD","LU1580142542.USD","BK0188","LU2495084118.USD","LU2148510915.USD","LU1781817850.SGD","LU1997245177.USD","BK0196","BK0276","LU0405327494.USD","LU1255011170.USD","LU2580892789.USD","BK1516","BK1521","LU0405327148.USD","LU1720050803.USD","BK0028","LU1794554557.SGD","LU1655091616.SGD","LU1064130708.USD","BK1564","BK1161","BK0183","BK1147","600030","BK0012","LU1328615791.USD","LU2289578879.USD","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793426","title":"君圣泰医药-B完成配售9871万股新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793426","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658793426?lang=zh_cn&edition=full","pubTime":"2026-08-09 10:04","pubTimestamp":1786241040,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端君圣泰医药-B(02511)公布,2026年8月7日完成配售9871万股新股,每股配售价2.28港元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-09/doc-inimsssr1943204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657620993","title":"君圣泰医药-B(02511):5日内累涨超30%,折价配售是妙手回春还是饮鸩止渴?","url":"https://stock-news.laohu8.com/highlight/detail?id=2657620993","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657620993?lang=zh_cn&edition=full","pubTime":"2026-08-08 19:03","pubTimestamp":1786186992,"startTime":"0","endTime":"0","summary":"2025年6月26日,君圣泰医药-B发布公告,宣布拟每股作价2.21港元折让约15%配售股份。2026年8月7日,君圣泰医药宣布新一轮配售9871万股已完成,净筹约2.22亿港元。当日公司股价大幅收涨16.84%,并在5个交易日内累涨30.77%。这也是君圣泰连续两年选择折价配售的主要原因之一。在安全性方面,HTD1801表现出良好的耐受性,严重不良事件发生率为3.8%,低于达格列净组的4.4%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180948291","title":"君圣泰医药-B:8月7日发行98,710,000股 占已发行股本17.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180948291","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180948291?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:56","pubTimestamp":1786092984,"startTime":"0","endTime":"0","summary":"君圣泰医药-B(股份代号:02511)于2026年8月7日发布翌日披露报表,宣布根据日期为2026年7月31日的配售协议及一般授权,于8月7日向市场发行98,710,000股新股,占发行前已发行股本的约17.28%。发行价格为每股2.28港元。发行完成后,公司已发行股本增至670,035,668股,库藏股数保持为0股。\n公司在公告中确认是次发行已获得董事会正式授权,并遵守相关上市规则及法律法规。上述公告由执行董事兼行政总裁刘利平博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"君圣泰医药-B:8月7日发行98,710,000股 占已发行股本17.28%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183181864","title":"君圣泰医药-B(02511)完成约2.25亿港元一般性授权配售 逾9,871万股新股发行价2.28港元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=1183181864","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183181864?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:52","pubTimestamp":1786092739,"startTime":"0","endTime":"0","summary":"2026年8月7日,君圣泰医药-B公告称,公司已完成根据一般性授权进行的新股份配售。此次配售的全部条件已达成,具体情况如下:。本次共向不少于六名独立承配人配售98,710,000股新股,每股配售价2.28港元。配售所得款项总额约为2.25亿港元,扣除相关费用及佣金后,公司实际可得净额约2.22亿港元。股本变动:配售完成后,君圣泰医药-B已发行股份由571,325,668股增至670,035,668股,新增股份占配售完成前已发行股份约17.28%,占扩大后已发行股份约14.73%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657977616","title":"君圣泰医药-B(02511.HK)完成配售9871万股 净筹约2.224亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657977616","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657977616?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:51","pubTimestamp":1786092665,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167009735","title":"君圣泰医药-B7月股份变动月报表:股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1167009735","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167009735?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:11","pubTimestamp":1785726719,"startTime":"0","endTime":"0","summary":"君圣泰医药-B2026年8月3日发布公告,披露截至2026年7月31日的证券变动月报表。报告期内,公司法定/注册股本及已发行股份数未发生任何增减变动。根据公告,君圣泰医药-B法定/注册股本数为1,000,000,000股,面值每股USD 0.0001,法定/注册股本总额维持USD 100,000不变。公告显示,君圣泰医药-B在报告期内无股份期权、权证、可转换债券或其他与发行人股份相关的相关变动及安排。截至2026年7月31日,公司总股本保持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655361066","title":"君圣泰医药-B(02511)拟折让约12.31%发行合共最多9900万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2655361066","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655361066?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:38","pubTimestamp":1785505102,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君圣泰医药-B(02511)发布公告,于2026年7月31日,本公司与独家配售代理订立配售协议,按配售协议的条款及条件,本公司同意发行配售股份,而独家配售代理同意作为本公司的代理,按尽力基准促使不少于六名独立承配人合共认购最多9900万股配售股份,配售价为每股配售股份2.28港元。每股配售股份2.28港元的配售价较于2026年7月31日(即配售协议日期)在联交所所报收市价每股 2.60港元折让约12.31%。假设所有配售股份均获发行,预期配售所得款项总额合共约为2.257亿港元,而预期配售所得款项净额(经扣除与配售有关的佣金及开支后)合共约为 2.23亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655361031","title":"君圣泰医药-B(02511.HK)拟折让约12.31%发行合共最多9900万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2655361031","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655361031?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:38","pubTimestamp":1785505102,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164723718","title":"君圣泰医药-B(02511)拟配售9,900万股 预计募资净额约2.23亿元港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164723718","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164723718?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:35","pubTimestamp":1785504945,"startTime":"0","endTime":"0","summary":"君圣泰医药-B7月31日收市后公告称,公司已与华兴证券(香港)有限公司签订配售协议,拟按每股2.28港元的价格配售最多9,900万股新股份,集资将按“尽力基准”引入不少于六名独立承配人。配售价格2.28港元较7月31日收市价2.60港元折让约12.31%,亦较7月30日前连续五个交易日平均收市价2.576港元折让约11.49%。本次配售预计可筹得资金总额约2.26亿元港元,扣除相关费用后,预计募集资金净额约2.23亿元港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650218243","title":"君圣泰医药-B(02511):HTD1801随机对照临床研究获积极评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2650218243","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650218243?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:24","pubTimestamp":1783682659,"startTime":"0","endTime":"0","summary":"上述研究结果及社论的发表,进一步体现了HTD1801的临床成果获得国际学术界的广泛关注与认可。基于此,HTD1801有潜力成为CKM领域的基础性治疗药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158238145","title":"君圣泰医药-B6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1158238145","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158238145?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:53","pubTimestamp":1782982437,"startTime":"0","endTime":"0","summary":"君圣泰医药-B于2026年7月2日公布截至2026年6月30日的股份变动月报表。报告显示,公司期内并无新增发行或股份变动,股本维持稳定。截至本期末,公司已发行股份总数为571,325,668股,暂无库藏股,报告期内未发生任何增发、购回或注销活动。本次月报表由执行董事兼行政总裁刘利平博士签署。根据公告披露,君圣泰医药-B截至2026年6月30日的股本结构与上月保持一致,未有股份发行及回购活动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328063","title":"格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓!","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647328063?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:08","pubTimestamp":1782709733,"startTime":"0","endTime":"0","summary":"本次评选共设有14个奖项","market":"us","thumbnail":"https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5373783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02279","02729","002600","002594","01384","300760","06668","02170","07688","01951","01768","02718","02408","06963","09992","06979","002714","01024","001248","09878","000951","02553","02511","01519","02687","01952","09880","00780","01497","02273","03690","02590","000039","09678","00917","02555","01833","09959","02105","02121","02661","02643","300364","03692","02526","00600","002779","002352","000338","01021"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129388527","title":"君圣泰医药-B(02511)授予董事股份购回授权 规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1129388527","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129388527?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:05","pubTimestamp":1780409152,"startTime":"0","endTime":"0","summary":"君圣泰医药-B于公告中披露,董事会已建议授权公司可在特定期限内回购不超过已发行股份总数10%的股份。公司于最后实际可行日期的已发行股本总数约为571,325,668股,此次获授权最多可回购57,132,566股。公告同时提到,公司将于2026年6月24日至6月29日暂停股份过户登记,股东如欲参加当日召开的股东周年大会并行使投票权,须于2026年6月23日16时30分前办理过户手续。董事会建议持股股东按照公告提示关注会议安排及授权事宜,以确保合理行使相关权益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"君圣泰医药-B(02511)授予董事股份购回授权 规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179825268","title":"君圣泰医药-B更新5月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1179825268","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179825268?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:53","pubTimestamp":1780303986,"startTime":"0","endTime":"0","summary":"2026年6月1日,君圣泰医药发布截至2026年5月31日的证券变动月报表。公告显示,公司法定/注册股本维持在1,000,000,000股普通股,面值每股0.0001美元,法定/注册股本总额为100,000美元,较上月无变化。截至2026年5月31日,公司已发行股份总数为571,325,668股,与上月持平,当月无新增发行、购回或注销活动,亦无公司库存股份产生。公眾持股比例维持符合香港联交所相关要求。公司确认本月所有股份相关事项均已遵循香港联交所《上市规则》及其他适用法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634049003","title":"格隆汇个股放量排行榜 | 5月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2634049003","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634049003?lang=zh_cn&edition=full","pubTime":"2026-05-09 17:30","pubTimestamp":1778319004,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示,上一交易日福田股份(08196)、优博控股(08529)、大行科工(02543)、信利国际(00732)、绿茶集团(06831)、兴证国际(06058)、马可数字科技(01942)、富通科技(00465)、粤港湾控股(01396)、千百度(01028)、大酒店(00045)、希慎兴业(00014)、长和(00001)、普拉达(01913)、中国海外发展(00688)、港铁公司","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/09173057055514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01396","00819","00290","08529","01358","01942","00215","00550","01028","02552","06978","00546","00014","00117","00045","00839","00434","00688","02718","00085","00017","01828","00412","00279","00069","00010","00465","00001","02543","02632","00365","06031","00243","00669","00118","01401","00732","02511","00752","02020","01140","01083","06669","01876","00012","00813","02418","00005","00066","01113"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2632316931","title":"君圣泰医药-B(02511):陈明宇获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2632316931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632316931?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:06","pubTimestamp":1777885601,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君圣泰医药-B(02511)发布公告,陈明宇先生(陈先生)已获委任为独立非执行董事、本公司审核委员会(审核委员会)主席及本公司薪酬委员会(薪酬委员会)成员,自2026年5月4日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136382844","title":"君圣泰医药-B更新4月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1136382844","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136382844?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:40","pubTimestamp":1777884033,"startTime":"0","endTime":"0","summary":"君圣泰医药-B于2026年5月4日发布截至2026年4月30日的月报表。公司全称为“君圣泰医药”,股票代码02511。报告显示,公司4月期间注册股本与已发行股份未发生变化。公司普通股法定/注册股本依旧为1,000,000,000股,面值每股USD 0.0001,截至4月末法定/注册股本合计USD 100,000,与上月持平。公司当月未发生新增发行、购回或注销股份等变动,也无涉及股票期权、可换股票据及其他协议或安排之更新。截至2026年4月底,公司股本总数保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118633582","title":"君圣泰医药-B(02511)聚焦CKM创新疗法,2025年度亏损收窄至2.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118633582","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118633582?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:35","pubTimestamp":1777462558,"startTime":"0","endTime":"0","summary":"君圣泰医药-B于本年度在糖尿病与心肝代谢系统疾病创新药领域继续深耕,核心产品及管线研究稳步推进。财务数据显示,2025年度公司年内亏损由上年的3.82亿元人民币收窄至2.32亿元人民币。行政开支约为5,910.20万元人民币,比去年同期减少27.2%。展望未来,君圣泰医药-B将继续深化在CKM领域的药物创新与临床研究,特别聚焦HTD1801及其他在研小分子药物在糖尿病、肥胖症、慢性肾脏病及相关肝病等领域的潜在应用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"君圣泰医药-B(02511)聚焦CKM创新疗法,2025年度亏损收窄至2.32亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630318900","title":"君圣泰医药-B(02511.HK)授出最高1500万港元贷款","url":"https://stock-news.laohu8.com/highlight/detail?id=2630318900","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630318900?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:47","pubTimestamp":1777301223,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨君圣泰医药-B(02511.HK)公告,于2026年4月27日,公司与借款人刘利平订立贷款协议,据此,公司同意向借款人提供最高融资额达1500万港元的贷款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260427/32180948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hightidetx.com","stockEarnings":[{"period":"1week","weight":0.1069},{"period":"1month","weight":0.375},{"period":"3month","weight":-0.0974},{"period":"6month","weight":0.3538},{"period":"1year","weight":0.1429},{"period":"ytd","weight":0.1932}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0507},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.0424},{"period":"1year","weight":0.0188},{"period":"ytd","weight":-0.0074}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"君圣泰医药是一家生物制药公司,专注于就代谢及消化系统疾病的治疗发现、开发及商业化多功能及多靶点疗法。该公司自主开发了多个候选产品的产品管线,涵盖代谢和消化疾病的多种适应症,其中部分产品处于临床阶段。该公司的核心产品HTD1801(小檗碱熊去氧胆酸盐)是一种新分子实体,作为肠肝抗炎代谢调节剂,靶向调节对人体代谢过程中至关重要的多个通路,包括与代谢及消化系统疾病相关的通路。该公司在美国、中国大陆、香港和澳大利亚开展业务。","exchange":"SEHK","name":"君圣泰医药-B","nameEN":"HIGHTIDE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君圣泰医药-B(02511)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君圣泰医药-B(02511)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君圣泰医药-B,02511,君圣泰医药-B股票,君圣泰医药-B股票老虎,君圣泰医药-B股票老虎国际,君圣泰医药-B行情,君圣泰医药-B股票行情,君圣泰医药-B股价,君圣泰医药-B股市,君圣泰医药-B股票价格,君圣泰医药-B股票交易,君圣泰医药-B股票购买,君圣泰医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君圣泰医药-B(02511)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君圣泰医药-B(02511)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}